AlloVir Announces Proposed Public Offering of Common Stock Cambridge, Mass.

AlloVir Announces Proposed Public Offering of Common Stock

Cambridge, Mass., June 21, 2023 AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that it has

commenced a proposed underwritten public offering of $75 million of shares of its common stock. AlloVir also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total

number of shares of its common stock offered in the public offering. All of the shares in the proposed offering are to be sold by AlloVir. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether

or when the offering may be completed, or as to the actual size or terms of the offering.

J.P. Morgan, Morgan Stanley and BofA Securities are acting as

joint book-running managers for the proposed offering.

The shares are being offered by AlloVir pursuant to an effective shelf registration statement that

was previously filed with the U.S. Securities and Exchange Commission (the SEC ). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary

prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC s website at www.sec.gov.

When available, copies of the preliminary prospectus supplement relating to the offering may be obtained from J.P. Morgan Securities LLC, Attention:

Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204 or email at prospectus-eq_fi@jpmchase.com; from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; or from

BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon, Charlotte, North Carolina 28255-0001, or by

email at dg.prospectus_requests@bofa.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities,

nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

AlloVir is a leading late clinical-stage

cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral

diseases. AlloVir s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

Media and Investor contact: